Glaukos registers for an initial public offering worth as much as $86 million for its iStent glaucoma treatment.
Glaukos yesterday registered for an initial public offering worth as much as $86.2 million.
The iStent made by Laguna Hills, Calif.-based Glaukos was the 1st micro-invasive glaucoma surgery device to hit the U.S. market. It's a tiny titanium stent designed to alleviate the intra-ocular pressure caused by glaucoma.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1cTm3U1
Cap comentari:
Publica un comentari a l'entrada